WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

Q2 2020 WAVE Life Sciences Ltd Earnings Call Transcript

Aug 10, 2020 / 12:30PM GMT
Release Date Price: €7.9 (+2.60%)
Operator

Good morning, and welcome to Wave Life Sciences Second Quarter 2020 Conference Call. (Operator Instructions) As a reminder, this call is being recorded and webcast.

I will now turn the call over to Kate Rausch, Head of Investor Relations at Wave Life Sciences. Please go ahead.

Kate Rausch
Wave Life Sciences Ltd. - Head of IR

Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's second quarter 2020 operating results. On the call with me today are Dr. Paul Bolno, our President and CEO; Dr. Mike Panzara, our Chief Medical Officer, Head of Therapeutics Discovery and Development; and David Gaiero, Interim CFO. Dr. Chandra Vargeese, Chief Technology Officer; and Dr. Ken Rhodes, SVP Therapeutics Discovery. Paul and Mike will provide opening remarks, after which Dave will discuss our second quarter financial results.

This morning, we issued a news release detailing our second quarter results. Please note that this news release is available on the Investors section of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot